Joshi Tejas P, Anvari Sara, Gupta Meera R, Davis Carla M, Hajjar Joud
Baylor College of Medicine, Houston, TX, United States.
Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.
Front Pediatr. 2021 Sep 29;9:646997. doi: 10.3389/fped.2021.646997. eCollection 2021.
The efficacy of dupilumab in pediatric patients with severe eczema presenting in the setting of elevated immunoglobulin E (IgE) levels and recurrent bacterial skin infections is not well-understood. Here we present the case of a child with elevated IgE levels in whom dupilumab treatment led to remarkable control of his eczema and recurrent skin infections. We also review the use of dupilumab in other patients with molecularly proven cases of hyper IgE (HIGE) syndrome. Our case supports the notion that dupilumab may have a seminal application in treating severe eczema that occurs in the setting of elevated IgE levels and recurrent bacterial skin infections.
度普利尤单抗在伴有免疫球蛋白E（IgE）水平升高及复发性细菌性皮肤感染的重度湿疹儿科患者中的疗效尚未完全明确。在此，我们报告一例IgE水平升高的儿童病例，其接受度普利尤单抗治疗后，湿疹及复发性皮肤感染得到显著控制。我们还回顾了度普利尤单抗在其他经分子学证实的高IgE（HIGE）综合征患者中的应用情况。我们的病例支持以下观点：度普利尤单抗在治疗伴有IgE水平升高及复发性细菌性皮肤感染的重度湿疹方面可能具有重要应用价值。
